Dear stakeholders, for information, the company have advised that they will not be making a submission to NICE for this indication in the foreseeable future. Therefore, in collaboration with the company, NICE has suspended this appraisal from its current work programme. NICE will continue to monitor any development and will update interested parties if the situation changes.
- Status:
- Suspended
- Technology type:
- Medicine
- Decision:
- Selected
- Prioritisation programme:
- Medicines evaluation
- Rationale:
Criteria within the 2024 Voluntary Scheme for Pricing, Access and Growth (VPAG) met as a significant licence extension.
- Process:
- STA Standard
- ID number:
- 12421
Email enquiries
If you have any queries please email Topic.Selection@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 25 June 2026 | Suspended. Dear stakeholders, for information, the company have advised that they will not be making a submission to NICE for this indication in the foreseeable future. Therefore, in collaboration with the company, NICE has suspended this appraisal from its current work programme. NICE will continue to monitor any development and will update interested parties if the situation changes. |
| 05 June 2026 | Awaiting development. Status change linked to topic prioritisation decision being set to Selected |
| 05 June 2026 | Prioritisation board meeting |
For further information on our processes and methods, please see our CHTE processes and methods manual